Claudio U. Köser

All parts of the WHO <i>Mycobacterium tuberculosis</i> mutation catalog need to be applied when evaluating its performance

The <i>ahpC</i> c−54t compensatory mutation is not always a valid surrogate for isoniazid resistance in <i>Mycobacterium tuberculosis</i>

Careful classification of potential bedaquiline resistance mutations is critical when analysing their clinical impact

The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis

Ancient and recent differences in the intrinsic susceptibility of <i>Mycobacterium tuberculosis</i> complex to pretomanid

Clinical standards for the dosing and management of TB drugs

Systematic review of mutations associated with resistance to the new and repurposed<i>Mycobacterium tuberculosis</i>drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid

Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex

MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era

Genomic identification of cryptic susceptibility to penicillins and β-lactamase inhibitors in methicillin-resistant Staphylococcus aureus

‘Those who cannot remember the past are condemned to repeat it’: Drug-susceptibility testing for bedaquiline and delamanid

Revised Interpretation of the Hain Lifescience GenoType MTBC To Differentiate <i>Mycobacterium canettii</i> and Members of the Mycobacterium tuberculosis Complex

World Tuberculosis Day March 24th 2019 Theme: “It’s TIME” — International Journal of Infectious Diseases Tuberculosis Theme Series

Reply to Dookie et al., “Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis”

A standardised method for interpreting the association between mutations and phenotypic drug resistance in<i>Mycobacterium tuberculosis</i>

What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis

Convergent evolution and topologically disruptive polymorphisms among multidrug-resistant tuberculosis in Peru

Role of Alanine Racemase Mutations in Mycobacterium tuberculosis <scp>d</scp> -Cycloserine Resistance

Some Synonymous and Nonsynonymous <i>gyrA</i> Mutations in Mycobacterium tuberculosis Lead to Systematic False-Positive Fluoroquinolone Resistance Results with the Hain GenoType MTBDR <i>sl</i> Assays

The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee

Whole-genome sequencing of multidrug-resistant Mycobacterium tuberculosis isolates from Myanmar

<i>dfrA thyA</i> Double Deletion in <i>para</i> -Aminosalicylic Acid-Resistant Mycobacterium tuberculosis Beijing Strains

Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin

Drug-resistance mechanisms and tuberculosis drugs